ATLANTA, July 11, 2018 /PRNewswire/ -- Alimera
Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the
commercialization and development of prescription ophthalmic
pharmaceuticals, today announced that 8 presentations on ILUVIEN
data have been accepted during the 36th Annual Meeting
of the American Society of Retina Specialists (ASRS) in
Vancouver, BC, Canada, July 20 through
25th.
"We are pleased with our podium presence this year at ASRS,"
said Dan Myers, CEO of Alimera. "The
data will reflect the benefit of ILUVIEN's CONTINUOUS MICRODOSING
in treating DME including a reduction in the recurrence of the
disease, a reduced number of injections compared to what DME
patients normally endure, and potential quality of life
improvements. There will also be additional data reinforcing the
predictability of an intraocular pressure rise with the use of
ILUVIEN."
The podium presentations are scheduled at the following dates
and times:
Tuesday, July 24, 2018, from
9:00 a.m. to 9:35 a.m.
- Reduction in the Frequency of Diabetic Macular Edema (DME)
Therapies Post-0.2 µg/Day Fluocinolone Acetonide (FAc) Implant
Treatment Results, Sam Mansour, MD,
MSc, FACS, FRCS(C)
- 2 Real-World Analyses of Treatment Burden Associated with
Intravitreal Injections for DME Prior to 0.2 µg/Day Fluocinolone
Acetonide (FAc), Nancy Holekamp,
MD
Tuesday, July 24, 2018, from
11:00 a.m. to 12:00 p.m.
- Effect on Treatment Burden Post-Versus Pre-ILUVIEN Based on
Prior DME Treatments, Caesar Luo,
MD
- Best Corrected Visual Acuity (BCVA) and Central Macular
Thickness (MAT) Outcomes After Fluocinolone Acetonide Intravitreal
Implant Injection, Dana Deupree,
MD
Tuesday, July 24, 2018, from
1:20 a.m. to 2:00 p.m.
- The Translation of CST to Visual Function: Persistent DME and
QOL Measures with FAc Implants in the FAME Study, Michael Singer, MD
The following posters and posters on demand will also be
available at the meeting:
Poster
- Choosing the Optimal Corticosteroid to Treat Diabetic Macular
Edema (DME) Prior to Using 0.2 ug/day Fluocinolone Acetonide
Implant (FAc; ILUVIEN), Joshua Mali, MD
Posters on Demand
- Effect of Fluocinolone Acetonide (FAc) 0.2µg/day (ILUVIEN)
Implant on the Decision to Drive in Patients with Differential
Control of DME, Seenu M. Hariprasad,
MD, Chicago, IL; Dilraj S. Grewal, MD, Durham, NC
- Prior Steroid Response as a Predictor of Real-World IOP Safety
with 0.2 μg/day Fluocinolone Acetonide (FAc) in Diabetic Macular
Edema (DME) Therapy (PALADIN & USER), Jay Prensky, MD
About ILUVIEN
www.ILUVIEN.com
ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is
a sustained release intravitreal implant approved in the U.S. to
treat diabetic macular edema in patients who have been previously
treated with a course of corticosteroids and did not have a
clinically significant rise in intraocular pressure. Each ILUVIEN
implant is designed to release submicrogram levels of fluocinolone
acetonide, a corticosteroid, for up to 36 months.
About Diabetic Macular Edema (DME)
DME, the primary cause of vision loss associated with diabetic
retinopathy, is a disease affecting the macula, the part of the
retina responsible for central vision. When the blood vessel
leakage associated with diabetic retinopathy results in swelling of
the macula, the condition is called DME. The onset of DME is
painless and may go unreported by the patient until it manifests
with the blurring of central vision or acute vision loss. The
severity of this blurring may range from mild to profound loss of
vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy
found that over a 10-year period approximately 19% of people with
diabetes included in the study were diagnosed with DME. All people
with type 1 or type 2 diabetes are at risk of developing DME. As
the population of people with diabetes increases, Alimera expects
the annual incidence of diagnosed DME to increase, as well.
About Alimera Sciences, Inc.
www.alimerasciences.com
Alimera, founded in June 2003, is
a pharmaceutical company that specializes in the commercialization
and development of prescription ophthalmic pharmaceuticals. Alimera
is presently focused on diseases affecting the back of the eye, or
retina, because these diseases are not well treated with current
therapies and will affect millions of people in our aging
populations. Alimera's commitment to retina specialists and their
patients is manifest in Alimera's product and development portfolio
designed to treat early- and late-stage diseases. For more
information, please visit www.alimerasciences.com.
For press
inquiries:
|
For investor
inquiries:
|
Katie
Brazel
|
CG Capital
|
for Alimera
Sciences
|
for Alimera
Sciences
|
404-317-8361
|
877-889-1972
|
kbrazel@bellsouth.net
|
investorrelations@cg.capital
|
|
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/alimera-sciences-announces-8-iluvien-presentations-at-the-2018-american-society-of-retina-specialists-annual-meeting-300678887.html
SOURCE Alimera Sciences, Inc.